The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The TAM family (TYRO3, AXL, MERTK) tyrosine kinases play roles in diverse biological processes including immune regulation, clearance of apoptotic cells, platelet aggregation, and cell proliferation, survival, and migration. While AXL and MERTK have been extensively studied, less is known about TYRO3. Recent studies revealed roles for TYRO3 in cancer and suggest TYRO3 as a therapeutic target in this context. TYRO3 is overexpressed in many types of cancer and functions to promote tumor cell survival and/or proliferation, metastasis, and resistance to chemotherapy. In addition, higher levels of TYRO3 expression have been associated with decreased overall survival in patients with colorectal, hepatocellular, and breast cancers. Here we review the physiological roles for TYRO3 and its expression and functions in cancer cells and the tumor microenvironment, with emphasis on the signaling pathways that are regulated downstream of TYRO3 and emerging roles for TYRO3 in the immune system. Translational agents that target TYRO3 are also described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“In the context of cancer, efferocytosis in the tumor microenvironment similarly leads to induction of anti-inflammatory type 2 cytokines and this shift in phenotype in the tumor microenvironment can suppress anti-tumor immunity [122].”
BackgroundSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 2×
“Mutations within the kinase domain have been identified in colon cancer (M592I) [73], lung cancer (N615K) [74], melanoma (W708fs*5) [75], brain cancer (A709T) [76], and AML (C690R) [77].”
BackgroundComprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Melanocyte biology and skin pigmentation
Lin, J. Y., & Fisher, D. E. (2007) · Nature · doi:10.1038/nature05660 · Cited by 1,379 · cited 1×
“function, and survival in melanocytes [103].”
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 1×
“Mutations in the extracellular and transmembrane domains leading to a premature stop codon have been described in melanoma (Q67 and H60Q) [50,79] and lung cancer (E340) [74].”
BackgroundRecurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
AceView: a comprehensive cDNA-supported gene and transcripts annotation
Thierry-Mieg, D., & Thierry-Mieg, J. (2006) · Genome Biology · doi:10.1186/gb-2006-7-s1-s12 · Cited by 629 · cited 2×
“Next generation computational modeling methods that rely on publicly-available cDNA and mRNA data predicted the existence of up to 9 TYRO3 splice variants containing overlapping exons, alternative splicing or intron retention, although these have not been verified in cell-based assays [13].”
MethodLemke, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009076 · Cited by 598 · cited 1×
“TYRO3 is a member of the TAM (TYRO3, AXL, MERTK) family of transmembrane receptor tyrosine kinases [1], which share overlapping functions in tumorigenesis and suppression of anti-tumor immunity [2].”
BackgroundTyro-3 family receptors are essential regulators of mammalian spermatogenesis
Lu, Q., Gore, M., Zhang, Q., Camenisch, T., Boast, S., Casagranda, F., Lai, C., Skinner, M. K., Klein, R., Matsushima, G. K., et al. (1999) · Nature · doi:10.1038/19554 · Cited by 514 · cited 2×
“modifications, localization and function [6,8,12].”
BackgroundNovel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495 · cited 2×
“In particular, numerous agents with inhibitory activity against MET also have potent activity against TYRO3, including BMS-777607 [127], foretinib [130,132], LDC1267 [133], LY2801653 [134], RXDX-106 [138] and sitravatinib [139].”
BackgroundWagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 2×
“Cytosolic domain mutations have been found in melanoma (R462Q) [75], pancreatic cancer (R514Q) [78], and colon cancer (G809D) [73].”
BackgroundThe E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Pathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Galectin-3 is a new MerTK-specific eat-me signal
Caberoy, N. B., Alvarado, G., Bigcas, J., & Li, W. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22955 · Cited by 176
Cited by
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139434 · Cited by 325
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
The complex roles of efferocytosis in cancer development, metastasis, and treatment
Tajbakhsh, A., Gheibi hayat, S. M., Movahedpour, A., Savardashtaki, A., Loveless, R., Barreto, G. E., Teng, Y., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111776 · Cited by 64
Widstrom, N. E., Andrianov, G. V., Heier, J. L., Heier, C., Karanicolas, J., & Parker, L. L. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00549 · Cited by 2
Metadata
- Authors
- Smart, S. K., Vasileiadi, E., Wang, X., DeRyckere, D., & Graham, D. K.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-11-29
- Volume
- 10
- Issue
- 12
- Pages
- 474
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2903179655
- Cited by
- 82
- References
- 15
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.